Short Interest in Lonza Group Ag (OTCMKTS:LZAGY) Rises By 102.6%

Lonza Group Ag (OTCMKTS:LZAGY) saw a large growth in short interest in May. As of May 15th, there was short interest totaling 55,395 shares, a growth of 102.6% from the April 30th total of 27,348 shares. Based on an average daily trading volume, of 159,592 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.0% of the company’s shares are sold short.

Lonza Group Stock Performance

Shares of LZAGY traded down $0.62 during mid-day trading on Monday, hitting $63.37. 34,198 shares of the company’s stock were exchanged, compared to its average volume of 88,577. The company has a quick ratio of 1.77, a current ratio of 2.24 and a debt-to-equity ratio of 0.42. Lonza Group has a 52 week low of $58.53 and a 52 week high of $73.85. The stock’s 50-day simple moving average is $63.04 and its 200-day simple moving average is $65.89.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Zacks Research raised shares of Lonza Group from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. Royal Bank Of Canada upgraded shares of Lonza Group from a “hold” rating to a “moderate buy” rating in a research report on Wednesday, February 11th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Lonza Group Company Profile

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.